Ionis Pharmaceuticals (IONS) Scheduled to Post Earnings on Tuesday

Ionis Pharmaceuticals (NASDAQ:IONS) will issue its quarterly earnings data before the market opens on Tuesday, May 7th. Analysts expect the company to announce earnings of ($1.07) per share for the quarter. Ionis Pharmaceuticals has set its FY 2024 guidance at EPS.Parties that are interested in registering for the company’s conference call can do so using this link.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its quarterly earnings results on Wednesday, February 21st. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.72. The company had revenue of $325.00 million for the quarter, compared to analyst estimates of $176.01 million. Ionis Pharmaceuticals had a negative net margin of 46.32% and a negative return on equity of 90.29%. Ionis Pharmaceuticals’s revenue for the quarter was up 113.8% on a year-over-year basis. During the same quarter last year, the business earned ($0.37) EPS. On average, analysts expect Ionis Pharmaceuticals to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Ionis Pharmaceuticals Stock Down 2.6 %

IONS stock opened at $41.97 on Monday. Ionis Pharmaceuticals has a 52 week low of $34.32 and a 52 week high of $54.44. The company has a debt-to-equity ratio of 3.18, a quick ratio of 5.83 and a current ratio of 5.90. The business has a fifty day simple moving average of $43.07 and a 200-day simple moving average of $46.99.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on IONS shares. Oppenheimer raised their price objective on Ionis Pharmaceuticals from $72.00 to $75.00 and gave the stock an “outperform” rating in a report on Tuesday, April 9th. Wolfe Research upgraded shares of Ionis Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $58.00 price target on the stock in a report on Wednesday, April 10th. JPMorgan Chase & Co. boosted their price objective on shares of Ionis Pharmaceuticals from $52.00 to $55.00 and gave the stock a “neutral” rating in a research note on Thursday, February 1st. StockNews.com raised shares of Ionis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, February 24th. Finally, William Blair reaffirmed an “outperform” rating on shares of Ionis Pharmaceuticals in a research report on Tuesday, April 9th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Ionis Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $57.67.

Insider Transactions at Ionis Pharmaceuticals

In related news, EVP Joseph Baroldi sold 4,006 shares of the stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $41.60, for a total value of $166,649.60. Following the completion of the transaction, the executive vice president now owns 19,631 shares of the company’s stock, valued at $816,649.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 2.65% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.